Difference between revisions of "NK- and T-cell lymphoma - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "|NR" to "|Not reported") |
|||
| Line 16: | Line 16: | ||
|- | |- | ||
|[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017] | |[https://doi.org/10.1182/blood-2016-12-756841 Kwong et al. 2017] | ||
| − | | | + | |Not reported |
| style="background-color:#ffffbe" |Case series | | style="background-color:#ffffbe" |Case series | ||
|- | |- | ||
Latest revision as of 11:00, 6 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NKTCL page for current regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Pembrolizumab monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Kwong et al. 2017 | Not reported | Case series |
Note: prospective trials are underway.
References
- Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed